Effects of various hypoglycaemic sulphonylureas on the cardiotoxicity of glycosides

1985 ◽  
Vol 28 (4) ◽  
pp. 367-370 ◽  
Author(s):  
G. Pog�tsa ◽  
M. Zs. Koltai ◽  
I. Balk�nyi ◽  
J. D�vai ◽  
V. Kiss
1970 ◽  
Vol 8 (10) ◽  
pp. 37-38

Glibenclamide (Daonil - Hoechst; Euglucon - Roussel) is claimed to be the most active and least toxic antidiabetic agent so far produced. Like other hypoglycaemic sulphonylureas it lowers the blood sugar at least in part by stimulating the release of endogenous insulin1 and is suitable for the treatment of maturity-onset diabetes.


1984 ◽  
Vol 105 (3) ◽  
pp. 385-390 ◽  
Author(s):  
Bo Hellman ◽  
Janove Sehlin ◽  
Inge-Bert Täljedal

Abstract. Six hypoglycaemic sulphonylurea compounds were compared with regard to their ability to bind to β-cell-rich pancreatic islets microdissected from ob/ob mice. Glibenclamide differed from carbutamide, tolbutamide, chlorpropamide, glibornuride and glipizide in not being rapidly bound to an equilibrium, but accumulating progressively in amounts far exceeding the water space. An inhibitor of the anion channels in the β-cell membrane, 4-acetamido-4'-isothiocyanate-stilbene-2,2'-disulphonic acid (SITS), suppressed the islet uptake of glibenclamide and to some extent also that of carbutamide and glibornuride. The unusual uptake characteristics of glibenclamide had their counterpart in a retardation of its maximal action in promoting the entry of Ca2+ into the β-cells.


The Lancet ◽  
1969 ◽  
Vol 293 (7587) ◽  
pp. 174-176 ◽  
Author(s):  
Ellis Samols ◽  
JeanM. Tyler ◽  
Pierre Mialhe

Sign in / Sign up

Export Citation Format

Share Document